UA82888C2 - Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators - Google Patents

Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators Download PDF

Info

Publication number
UA82888C2
UA82888C2 UAA200601432A UAA200601432A UA82888C2 UA 82888 C2 UA82888 C2 UA 82888C2 UA A200601432 A UAA200601432 A UA A200601432A UA A200601432 A UAA200601432 A UA A200601432A UA 82888 C2 UA82888 C2 UA 82888C2
Authority
UA
Ukraine
Prior art keywords
yloxy
benzothiazol
benzyl
piperidin
group
Prior art date
Application number
UAA200601432A
Other languages
English (en)
Ukrainian (uk)
Inventor
James P Edwards
Kevin L Tace
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UA82888C2 publication Critical patent/UA82888C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UAA200601432A 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators UA82888C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024050 WO2005012296A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
UA82888C2 true UA82888C2 (en) 2008-05-26

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200601432A UA82888C2 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
UAA200601433A UA87986C2 (ru) 2003-07-28 2004-07-27 Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение как lta4h модуляторов

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200601433A UA87986C2 (ru) 2003-07-28 2004-07-27 Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение как lta4h модуляторов

Country Status (29)

Country Link
US (2) US20050043379A1 (ru)
EP (2) EP1660491B1 (ru)
JP (2) JP2007500703A (ru)
KR (2) KR20060054408A (ru)
CN (2) CN1856490A (ru)
AR (2) AR045729A1 (ru)
AT (2) ATE403654T1 (ru)
AU (2) AU2004261610B2 (ru)
BR (2) BRPI0412345A (ru)
CA (2) CA2534228A1 (ru)
CY (1) CY1108560T1 (ru)
DE (2) DE602004015620D1 (ru)
DK (2) DK1660491T3 (ru)
ES (2) ES2313079T3 (ru)
HK (2) HK1092790A1 (ru)
HR (2) HRP20060041B1 (ru)
IL (1) IL173372A (ru)
MY (1) MY145080A (ru)
NO (2) NO20060771L (ru)
NZ (2) NZ544938A (ru)
PL (2) PL1660492T3 (ru)
PT (2) PT1660492E (ru)
RU (2) RU2359970C2 (ru)
SG (2) SG129449A1 (ru)
SI (2) SI1660492T1 (ru)
TW (2) TW200520756A (ru)
UA (2) UA82888C2 (ru)
WO (2) WO2005012297A1 (ru)
ZA (2) ZA200601720B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500703A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびlta4hモジュレーターとしてのそれらの使用
EA200702128A1 (ru) * 2005-03-31 2008-04-28 Янссен Фармацевтика Н.В. Фенильные и пиридильные модуляторы lta4h
DK1877379T3 (da) 2005-04-13 2013-04-08 Astex Therapeutics Ltd Hydroxybenzamidderivater og anvendelse heraf som inhibitorer af hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
DE602006020049D1 (de) * 2005-09-02 2011-03-24 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
EA017618B1 (ru) * 2005-09-21 2013-01-30 Декод Дженетикс Ехф Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
US7576102B2 (en) 2005-12-21 2009-08-18 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
US7674802B2 (en) 2005-12-21 2010-03-09 Decode Genetics, Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
ES2614090T3 (es) * 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
EP1987009A1 (en) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
EP2134704B1 (en) * 2007-03-08 2010-09-22 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
TW200932236A (en) 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
US20090176785A1 (en) * 2007-11-16 2009-07-09 Abbott Laboratories Method of treating arthritis
JP5530423B2 (ja) * 2008-04-11 2014-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ロイコトリエンa4加水分解酵素の調節因子としてのチアゾロピリジン−2−イルオキシ−フェニル及びチアゾロピラジン−2−イルオキシ−フェニルアミン
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
SI2294066T1 (sl) 2008-04-28 2014-12-31 Janssen Pharmaceutica N.V. Benzoimidazoli kot inhibitorji prolil-hidroksilaze
MX2011012190A (es) * 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN106038556A (zh) 2011-10-25 2016-10-26 詹森药业有限公司 1‑(5,6‑二氯‑1h‑苯并[d]咪唑‑2‑基)‑1h‑吡唑‑4‑羧酸的葡甲胺盐制剂
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス,インコーポレイテッド ロイコトリエンa4加水分解酵素の阻害剤
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
EA028921B1 (ru) * 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
DK3307734T3 (da) 2015-06-09 2020-01-27 Abbvie Inc Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme
CA3045970A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希(南京)药物研发有限公司 一种雷贝拉唑杂质的制备方法
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
CA3202720A1 (en) * 2020-11-19 2022-05-27 Telo Therapeutics, Inc. Small molecule compounds and compositions
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
JP2007500703A (ja) * 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびlta4hモジュレーターとしてのそれらの使用
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.

Also Published As

Publication number Publication date
HK1090359A1 (en) 2006-12-22
KR101149379B1 (ko) 2012-06-28
ES2311858T3 (es) 2009-02-16
WO2005012297A9 (en) 2007-01-04
TWI362383B (en) 2012-04-21
NO20060771L (no) 2006-04-21
SG129449A1 (en) 2007-02-26
SI1660492T1 (sl) 2009-02-28
AR045730A1 (es) 2005-11-09
ATE405562T1 (de) 2008-09-15
ATE403654T1 (de) 2008-08-15
TW200523255A (en) 2005-07-16
CY1108560T1 (el) 2014-04-09
CN100591679C (zh) 2010-02-24
NZ544970A (en) 2009-02-28
RU2359970C2 (ru) 2009-06-27
WO2005012296A1 (en) 2005-02-10
EP1660491B1 (en) 2008-08-06
RU2006102510A (ru) 2006-07-27
CN1856490A (zh) 2006-11-01
AU2004261628B2 (en) 2011-05-12
UA87986C2 (ru) 2009-09-10
DE602004015620D1 (de) 2008-09-18
KR20060054408A (ko) 2006-05-22
PT1660492E (pt) 2008-11-13
JP2007500703A (ja) 2007-01-18
WO2005012297A1 (en) 2005-02-10
RU2373204C2 (ru) 2009-11-20
DE602004016002D1 (de) 2008-10-02
HK1092790A1 (en) 2007-02-16
AU2004261610A1 (en) 2005-02-10
BRPI0413072A (pt) 2006-10-03
RU2006102508A (ru) 2006-07-27
EP1660491A1 (en) 2006-05-31
US20050043379A1 (en) 2005-02-24
JP4726238B2 (ja) 2011-07-20
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
SI1660491T1 (sl) 2009-02-28
ZA200601720B (en) 2007-11-28
KR20060057593A (ko) 2006-05-26
JP2007500706A (ja) 2007-01-18
EP1660492B1 (en) 2008-08-20
HRP20060041A2 (en) 2006-11-30
US20050043378A1 (en) 2005-02-24
EP1660492A1 (en) 2006-05-31
SG130192A1 (en) 2007-03-20
PT1660491E (pt) 2008-10-10
PL1660491T3 (pl) 2009-01-30
NZ544938A (en) 2009-05-31
TW200520756A (en) 2005-07-01
HRP20060041B1 (hr) 2014-06-06
CA2534228A1 (en) 2005-02-10
IL173372A0 (en) 2006-06-11
CN1860117A (zh) 2006-11-08
ZA200601716B (en) 2007-05-30
AU2004261610B2 (en) 2010-05-20
DK1660492T3 (da) 2008-11-03
PL1660492T3 (pl) 2009-01-30
HRP20060039A2 (en) 2006-08-31
DK1660491T3 (da) 2008-11-10
MY145080A (en) 2011-12-15
BRPI0412345A (pt) 2006-10-03
NO20060823L (no) 2006-03-15
AU2004261628A1 (en) 2005-02-10
ES2313079T3 (es) 2009-03-01
IL173372A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
UA82888C2 (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
JP4787529B2 (ja) 医薬組成物
ES2400179T3 (es) 2-3-dihidro-6-nitroimidazol[2,1-b]oxazoles
WO2008100564A1 (en) Lta4h modulators and uses therof
BRPI0620251A2 (pt) compostos de nitroimidazol
EP2513066A1 (de) Inhibitoren der sphingosinkinase
SG174389A1 (en) Amide derivative
WO2019011715A1 (en) PYRAZOLO-QUINAZOLINE DERIVATIVES AS INHIBITORS OF CHOLINE KINASE
JP5345174B2 (ja) 医薬組成物
CZ284754B6 (cs) N-(Aryloxyalkyl)heteroaryl-8-azabicyklo/3.2.1/ oktany, meziprodukty a způsob jejich přípavy a jejich použití jako léčiv
CA3001649C (en) Dopamine d3 receptor antagonists having a morpholine moiety
WO2004058702A2 (en) 4-[(4-(carboxyethyl) piperidinyl) methyl] pyrrolidines as modulators of chemokine receptor activity
MXPA06001122A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
MXPA06001121A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators